.jpg)
.png)
There is a large population >80 in the U.S., some who have either been advised to or chose to discontinue statin therapy. Randomized clinical trials have typically excluded very elderly subjects or group all elderly into age >65. There are vast differences in this population in terms of frailty vs. vigorousness, comorbidities, motivation, and financial resources.
Article By:
Cardiovascular Nurse Practitioner
Montrose Memorial Hospital
Montrose, CO
Diplomate, Accreditation Council for Clinical Lipidology
Often there is a dichotomy regarding information published in the lay press versus what is presented in the medical literature. So it’s nice when both agree, except on those rare occasions, when both get it wrong.
Article By:
Director, Advance Lipid Management Program
Tyler Heart Institute, Community Hospital of the
Monterey Peninsula
Monterey, CA
Diplomate, American Board of Clinical Lipidology
Evaluation of a patient’s risk for cardiovascular disease (CVD) is the basis of deciding whether to institute statin therapy. The 2013 ACC/AHA Guidelines on the Assessment of Cardiovascular Risk recommend using the Pooled Cohort Equation to predict the 10-year risk of having an atherosclerotic cardiovascular disease (ASCVD) event in non-Hispanic Whites and African Americans, 40 to 79 years of age.
Article By:
Clinical Professor of Medicine Thomas Jefferson University
Medical Director of Cardiovascular Prevention
Christiana Care Health System
Newark, DE
Diplomate, American Board of Clinical Lipidology
Cardiovascular Fellow
Christiana Health Care System
Newark, DE
Statins currently stand as the cornerstone of therapeutic strategies for the reduction of atherosclerotic cardiovascular events.1–4 However, despite their chronicled successes over the past 30 years since the U.S.
Article By:
Clinical Pharmacist, Medication Management
Park Nicollet Health System
St. Louis Park, MN
Diplomate, Accreditation Council for Clinical Lipidology
Recent clinical trial data has strengthened the argument that lowering low-density lipoprotein cholesterol (LDL-C) to levels well below those previously targeted provides incremental benefit in terms of lowering the risk of atherosclerotic cardiovascular disease (ASCVD).1 The increased use of high-intensity statins, irrespective of baseline LDL-C, has resulted in clinicians more frequently encountering LDL-C levels below 40 mg/dL.
Article By:
Clinical Pharmacy Specialist, Clinical Pharmacy Cardiac Risk Service
Kaiser Permanente of Colorado
Clinical Assistant Professor
University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences,
Aurora, CO
Diplomate, Accreditation Council for Clinical Lipidology
Clinical Pharmacy Specialist, Clinical Pharmacy Cardiac Risk Service
Kaiser Permanente of Colorado
Clinical Assistant Professor
University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences,
Aurora, CO
The approach to understanding hypercholesterolemia, hypertriglyceridemia, or both, starts with consideration of the underlying lipoprotein abnormalities present.1,2 This is followed by asking to what degree genetic or acquired causes explain the observed abnormalities.
Article By:
Feinberg School of Medicine
Division of Cardiology
Northwestern University
Chicago, IL
Feinberg School of Medicine
Division of Cardiology
Northwestern University
Chicago, IL
Feinberg School of Medicine
Division of Cardiology
Northwestern University
Chicago, IL
Bonow Professor of Medicine
Feinberg School of Medicine
Division of Cardiology
Northwestern University
Chicago, IL
Diplomate, American Board of Clinical Lipidology
JACKSONVILLE, Fla. (September 2016) — The Foundation of the National Lipid Association, in conjunction with National Cholesterol Education Month, will launch the RADAR Campaign (RADAR: RAre Disease AwaReness) providing resources and tools to both patients and healthcare professionals designed to help improve the identification and management of rare lipid disorders, including FH, FCS, and LAL-D.
The National Lipid Association (NLA) is committed to enhancing the practice of lipid management in clinical medicine. A major component is having access to all therapies to properly treat patients with the management of lipid disorders.
JACKSONVILLE, FL -- (Marketwired - August 29, 2016) - A
Patients of all ages and with all kinds of problems seek help in our busy family medicine clinic (10 providers, 33,000 visits a year), which is part of a four-clinic network of the Oregon Health & Science University (OHSU) Family Medicine Department. I work independently (although we do collaborate) from the OHSU Preventive Cardiology Division as the only lipidologist within our department, taking referrals from my colleagues.
Article By:
Assistant Professor of Family Medicine
Oregon Health and Science University
Portland, OR
Diplomate, American Board of Clinical Lipidology